Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10373066" target="_blank" >RIV/00216208:11110/18:10373066 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/18:10373066

Výsledek na webu

<a href="https://doi.org/10.1016/j.msard.2017.11.018" target="_blank" >https://doi.org/10.1016/j.msard.2017.11.018</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2017.11.018" target="_blank" >10.1016/j.msard.2017.11.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Popis výsledku v původním jazyce

Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to &quot;sphingosine-1-phosphate&quot;(S1P) receptors that are expressed in a wide range of cells, including lymphocytes. Under the effect of fingolimod, lymphocytes are retained in lymphoid tissues through the regulation of S1P(1) receptors. The aim of the present study was to assess whether the degree of lymphopenia was correlated to the positive treatment response of RRMS patients with fingolimod. Methods: Data was sourced from the MSBase Registry. Patients were divided into two groups, according to the lymphocyte count on peripheral blood examination. Annualized Relapse Rate (ARR), time to first relapse and time to six-month confirmed disability progression were compared between groups. Results: Group one consisted of 202 patients who reached 750 lymphocytes/mm(3) during treatment while the comparison group two included 101 patients who never reached less than 1000 lymphocytes/mm(3) in peripheral blood during the observation period. There were no differences between groups in ARR, time to first relapse or time to six-month confirmed disability progression. Conclusion: The degree of lymphopenia in peripheral blood was not associated to the positive treatment response of fingolimod in RRMS patients.

Název v anglickém jazyce

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Popis výsledku anglicky

Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to &quot;sphingosine-1-phosphate&quot;(S1P) receptors that are expressed in a wide range of cells, including lymphocytes. Under the effect of fingolimod, lymphocytes are retained in lymphoid tissues through the regulation of S1P(1) receptors. The aim of the present study was to assess whether the degree of lymphopenia was correlated to the positive treatment response of RRMS patients with fingolimod. Methods: Data was sourced from the MSBase Registry. Patients were divided into two groups, according to the lymphocyte count on peripheral blood examination. Annualized Relapse Rate (ARR), time to first relapse and time to six-month confirmed disability progression were compared between groups. Results: Group one consisted of 202 patients who reached 750 lymphocytes/mm(3) during treatment while the comparison group two included 101 patients who never reached less than 1000 lymphocytes/mm(3) in peripheral blood during the observation period. There were no differences between groups in ARR, time to first relapse or time to six-month confirmed disability progression. Conclusion: The degree of lymphopenia in peripheral blood was not associated to the positive treatment response of fingolimod in RRMS patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

105-108

Kód UT WoS článku

000425903700023

EID výsledku v databázi Scopus

2-s2.0-85034851540